Abnormal liver function tests and metabolic syndrome - Is fatty liver related to risks for atherosclerosis beyond obesity?

Internal Medicine

Volumn 48, Issue 18, 2009, Pages 1573-1574

  Sakurai, Masaru ^a   Takamura, Toshinari ^b   Miura, Katsuyuki ^c   Kaneko, Shuichi ^b   Nakagawa, Hideaki ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Fatty liver; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; FATTY LIVER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; JAPANESE; LIPID METABOLISM; LIVER FUNCTION TEST; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; LIVER FUNCTION TESTS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 70349488344     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2517     Document Type: Editorial

References (14)

1. Oda E, Kawai R, Watanabe K, Sukumaran V. Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women. Intern Med 48: 1343-1350, 2009.
2. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27: 127-133, 2007.
3. Meisinger C, Döring A, Schneider A, Löwel H; KORA Study Group. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 189: 297-302, 2006.
4. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191: 391-396, 2007.
5. Devers MC, Campbell S, Shaw J, Zimmet P, Simmons D. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabet Med 25: 523-529, 2008.
6. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104: 861-867, 2009.
7. André P, Balkau B, Vol S, Charles MA, Eschw??ge E; DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 30: 2355-2361, 2007.
8. Sakurai M, Takamura T, Ota T, et al. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol 42: 312-317, 2006.
9. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191: 235-240, 2007.
10. McKimmie RL, Daniel KR, Carr JJ, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103: 3029-3035, 2008.
11. McCullough AJ. The epidemiology and risk factors of NASH. In: Fatty Liver Disease: NASH and Related Disorders. Farrell GC, George J, de la M Hall P, McCullough AJ, Eds. Blackwell Publishing, Malden, MA, 2005: 23-37.
12. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41: 372-379, 2005.
13. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL; Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793, 2007.
14. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22: 1086-1091, 2007.